Laetitia Marzi
Inserm(FR)Institut de Recherche en Cancérologie de Montpellier(FR)
Publications by Year
Research Areas
Cancer therapeutics and mechanisms, PARP inhibition in cancer therapy, Colorectal Cancer Treatments and Studies, DNA Repair Mechanisms, Synthesis and Catalytic Reactions
Most-Cited Works
- → The PGD2 pathway, independently of FGF9, amplifies SOX9 activity in Sertoli cells during male sexual differentiation(2009)181 cited
- → MAPK14/p38α confers irinotecan resistance to TP53-defective cells by inducing survival autophagy(2012)95 cited
- → Targeting the p38 MAPK Pathway Inhibits Irinotecan Resistance in Colon Adenocarcinoma(2010)87 cited
- → The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib(2019)56 cited
- → FOXO3a and the MAPK p38 are activated by cetuximab to induce cell death and inhibit cell proliferation and their expression predicts cetuximab efficacy in colorectal cancer(2016)51 cited
- → Novel Fluoroindenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors(2018)41 cited
- → The Indenoisoquinoline LMP517: A Novel Antitumor Agent Targeting both TOP1 and TOP2(2020)15 cited
- → An intron proximal to a PTC enhances NMD in Saccharomyces cerevisiae(2017)4 cited
- → Abstract 2794: Indotecan (LMP400), imidotecan (LMP776) and LMP744: A new class of non-camptothecin Top1 inhibitors selective for homologous recombination deficient (HRD) cells(2017)2 cited
- → Supplementary Figure 4 from The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib(2023)